Nemolizumab Shows Positive Results in Maruho’s Phase 3 Study in Atopic Dermatitis

TOKYO, April 18, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Maruho Co., Ltd. reported results from a phase 3 study investigating the efficacy and safety of nemolizumab (CIM331) with atopic dermatitis patients 13 years of age or older who had moderate-to-severe pruritus. Nemolizuab was created by Chugai, and is currently under development in Japan by Maruho for atopic dermatitis. Press release by Maruho issued on April 18, 2019: Maruho Announces Positive Phase 3 Results of Nemolizumab in Patients with Atopic Dermatitis http://www.maruho.co.jp/english/release/ [Note] Press release issued on September 28, 2016: Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market https://www.chugai-pharm.co.jp/english/news/detail/20160928150000_121.html

The release as fetched from its publisher. chugai-pharm.co.jp ↗